Improved outcomes for children with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical, and clinical arenas spanning cellular immunology, gene therapy, and cell-processing technologies have paved the way for clinical applications of chimeric antigen receptor–based therapies. This is a new form of targeted immunotherapy that merges the exquisite targeting specificity of monoclonal antibodies with the potent cytotoxicity, potential for expansion, and long-term persistence provided by cytotoxic T cells. Although this field is still in its infancy, clinical trials have already shown clinically significant antitumor activity in neuroblastoma, chronic lymphocytic leukemia, and B-cell lymphoma, and trials targeting a variety of other adult and pediatric malignancies are under way. Ongoing work is focused on identifying optimal tumor targets and elucidating and manipulating both cell- and host-associated factors to support expansion and persistence of the genetically engineered cells in vivo. In pediatric oncology, CD19 and GD2 are compelling antigens that have already been identified for targeting pre-B acute lymphoblastic leukemia and neuroblastoma, respectively, with this approach, but it is likely that other antigens expressed in a variety of childhood cancers will also soon be targeted using this therapy. The potential to target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can be made opens up an entirely new arena for targeted therapy of childhood cancer. Clin Cancer Res; 18(10); 2780–90. ©2012 AACR.

Cell therapy for cancer is crossing the threshold of clinical activity, as trials in both adult and pediatric oncology have now shown unquestionable clinical responses (1–7). Historically, cell-based therapies have focused on cytolytic T cells targeting MHC-restricted antigens. Although this approach remains promising, its efficacy and applicability are limited by the need to enhance the affinity of naturally occurring T-cell receptors (TCR) that target most tumor antigens, and the tendency for tumors to downregulate MHC molecules. Furthermore, targeting MHC-restricted antigens is particularly challenging for pediatric cancer and other rare tumors because immunodominant epitopes have not been defined for most MHC alleles, and the difficulty of targeting a rare tumor in a limited population that expresses a particular MHC allele severely affects feasibility and applicability. For these reasons, chimeric antigen receptors (CAR; Fig. 1), which harness the potent cytolytic capacity of expanded effector populations with MHC-unrestricted targeting, are receiving increasing attention and represent a promising new therapeutic modality for childhood cancer. Below, we discuss the progress that has been made in this young field, as well as the challenges that remain to be overcome.

Figure 1.

Current CAR design allows for MHC-independent antigen recognition and incorporates costimulatory signal(s) endowing the transduced T cell with potent cytotoxic activity. In contrast to the TCR, which recognizes peptide in the context of MHC and provides signal 1, CARs interact in an MHC-independent manner. All CARs must provide signal 1 in the form of the TCR ζ activating subunit (first-generation), but the addition of one (second-generation) or 2 (third-generation) costimulatory signals (CD28, 4-1BB, or OX40) provides the CAR-transduced T cell with both signals 1 and 2, leading to full activation, proliferation, and cytotoxicity.

Figure 1.

Current CAR design allows for MHC-independent antigen recognition and incorporates costimulatory signal(s) endowing the transduced T cell with potent cytotoxic activity. In contrast to the TCR, which recognizes peptide in the context of MHC and provides signal 1, CARs interact in an MHC-independent manner. All CARs must provide signal 1 in the form of the TCR ζ activating subunit (first-generation), but the addition of one (second-generation) or 2 (third-generation) costimulatory signals (CD28, 4-1BB, or OX40) provides the CAR-transduced T cell with both signals 1 and 2, leading to full activation, proliferation, and cytotoxicity.

Close modal

CARs (historically referred to as T-bodies) were first generated in 1989 by Eshhar and colleagues as fusions of antibody and TCR subunits that, when expressed on T cells, mediated MHC-independent T-cell activation (8–10). Although early results provided proof-of-principle, T-cell activation was not robust, and therefore CAR technologies were gradually optimized via modification and addition of subunits to increase signaling potency. The structure has evolved over the last 2 decades to most commonly incorporate a single-chain variable fragment (scFv) derived from a monoclonal antibody (mAb) plus the signaling motif from the TCR ζ chain [referred to as a first-generation CAR (Fig. 1; ref. 11)]. A major advance was made when 1 (second-generation CAR) or 2 (third-generation CAR) costimulatory activating motifs from CD28, 4-1BB (CD137), and/or CD134 (OX-40) were incorporated into CARs, leading to enhanced proliferation, cytotoxicity, and persistence in vivo (Fig. 1; refs. 3, 12–15). Beyond the general principle that CARs that incorporate costimulatory signals are more potent, it remains unclear whether any particular costimulatory molecule is superior to another, and to what extent the beneficial effects of any or all costimulators can be imparted by signaling during the expansion process without incorporating the molecule into the CAR itself (15–18). Of note, incorporation of the 4-1BB signaling motif into a CAR was recently reported to result in more robust proliferation in vitro compared with CD28 (15). These 2 costimulatory domains have not been compared in controlled clinical trials as yet; however, 2 of 3 patients with refractory chronic lymphocytic leukemia (CLL) treated with an anti-CD19 CAR that used 4-1BB as its costimulatory signal achieved durable (1 year) complete remissions, and the third achieved a partial remission (3, 19).

Multiple methods can be used to introduce CARs into effector cells. The most common approach uses γ retroviruses, which efficiently and stably integrate the receptor sequence into the target cell genome (6, 20, 21). Thus far, this approach has proved to be safe for transduction of mature T cells, although concerns remain that insertional mutagenesis or immune responses against retroviral antigens could occur (22, 23). Similarly, lentiviral transduction of the CAR sequence into expanding T cells has also been shown to be a safe and successful approach (3, 15). Nonviral methods, such as the use of transposon-based systems and direct RNA transfection (24–27), are also being explored. These methods are likely to be less costly to develop (25), and RNA transfection has the potential for self-limited expression in cases where permanent expression may be undesirable. In cases where permanent expression systems are used, some investigators have incorporated suicide genes, such as the herpes simplex thymidine kinase (TK) gene, or an inducible caspase 9 protein that can be activated by specific drugs and eradicate the genetically engineered cells if adverse effects occur following adoptive transfer (28–30).

CAR specificity is most commonly endowed by an scFv derived from phage display or from mAbs raised against cell-surface antigens, although in some cases receptor ligands have been used (31, 32). It is generally assumed that a high-affinity antigen-binding domain that targets a plentiful tumor cell-surface antigen with limited expression on normal tissue is desirable; however, the precise and relative importance of affinity and target expression levels have not been defined, and very few antigens show exclusive expression on tumors. The risk–benefit ratio of any particular CAR-expressing T lymphocyte is driven largely by properties of the target, because targets with vital organ expression will induce off-tumor, on-target effects. Depending on the tissues in which the target is expressed, this could result in minimal or unacceptable toxicity. B-cell malignancies provide several attractive CAR targets because mAbs are available to target several B-cell surface antigens, and the mature B-cell compartment is considered to be relatively expendable, at least temporarily, in patients with hematologic malignancies. Thus, CARs targeting CD20 (33, 34), CD19 (20), and CD22 (35) have been developed, and many trials for pediatric B-cell precursor acute lymphoblastic leukemia (pre-B ALL) are under way or anticipated (Table 1). CARs that target CD30 (18, 36) and ROR1 for lymphomas (37) are under study as well and may also be applicable to pediatric hematologic malignancies.

Table 1.

Active clinical trials of CAR therapy in children with cancer

LocationTargetMalignanciesCommentsTrial number
Baylor/Texas Children's Hospital/The Methodist Hospital CD19 pre-B ALL, B-cell lymphomas 50% second generation (CD28) NCT00586391 
   50% first generation  
Baylor/Texas Children's Hospital/The Methodist Hospital CD19 pre-B ALL, B-cell lymphomas multivirus CTL transduced post-BMT NCT00840853 
   second generation (CD28)  
Children's Hospital of Philadelphia/University of Pennsylvania CD19 pre-B ALL, B-cell lymphomas CLL (adults) lentiviral transduction NCT01029366 
   second generation (4–1BB)  
Children's Hospital of Philadelphia/University of Pennsylvania CD19 pre-B ALL, B-cell lymphomas CLL (adults) donor T cells given for relapse after allo SCT pending 
   second generation (4-1BB)  
University College of London CD19 pre-B ALL, B-cell lymphomas donor EBV CTL post-BMT with EBV-LCL vaccine NCT01195480 
   second generation (CD28)  
Memorial Sloan-Kettering Cancer Center CD19 pre-B ALL, B-cell lymphomas donor EBV CTL post-BMT NCT01430390 
   second generation (CD28)  
The University of Texas MD Anderson Cancer Center CD19 pre-B ALL, B-cell lymphomas donor-derived modified T cells after umbilical cord transplant NCT01362452 
National Cancer Institute Pediatric Oncology Branch CD19 pre-B ALL, B-cell lymphomas second generation (CD28) pending 
Baylor/Texas Children's Hospital/The Methodist Hospital Her2 Her2+ sarcomas second generation (CD28) NCT00902044 
  glioblastoma autologous CMV CTL (glioblastoma) NCT01109095 
Baylor/Texas Children's Hospital/The Methodist Hospital CD30 Hodgkin and CD30+ non-Hodgkin lymphoma autologous EBV CTLs NCT01192464 
   first generation  
   autologous T cells NCT01316146 
   second generation (CD28)  
Baylor/Texas Children's Hospital GD2 neuroblastoma autologous EBV CTLs NCT00085930 
   first generation  
   autologous polyclonal CTLs  
   first generation  
LocationTargetMalignanciesCommentsTrial number
Baylor/Texas Children's Hospital/The Methodist Hospital CD19 pre-B ALL, B-cell lymphomas 50% second generation (CD28) NCT00586391 
   50% first generation  
Baylor/Texas Children's Hospital/The Methodist Hospital CD19 pre-B ALL, B-cell lymphomas multivirus CTL transduced post-BMT NCT00840853 
   second generation (CD28)  
Children's Hospital of Philadelphia/University of Pennsylvania CD19 pre-B ALL, B-cell lymphomas CLL (adults) lentiviral transduction NCT01029366 
   second generation (4–1BB)  
Children's Hospital of Philadelphia/University of Pennsylvania CD19 pre-B ALL, B-cell lymphomas CLL (adults) donor T cells given for relapse after allo SCT pending 
   second generation (4-1BB)  
University College of London CD19 pre-B ALL, B-cell lymphomas donor EBV CTL post-BMT with EBV-LCL vaccine NCT01195480 
   second generation (CD28)  
Memorial Sloan-Kettering Cancer Center CD19 pre-B ALL, B-cell lymphomas donor EBV CTL post-BMT NCT01430390 
   second generation (CD28)  
The University of Texas MD Anderson Cancer Center CD19 pre-B ALL, B-cell lymphomas donor-derived modified T cells after umbilical cord transplant NCT01362452 
National Cancer Institute Pediatric Oncology Branch CD19 pre-B ALL, B-cell lymphomas second generation (CD28) pending 
Baylor/Texas Children's Hospital/The Methodist Hospital Her2 Her2+ sarcomas second generation (CD28) NCT00902044 
  glioblastoma autologous CMV CTL (glioblastoma) NCT01109095 
Baylor/Texas Children's Hospital/The Methodist Hospital CD30 Hodgkin and CD30+ non-Hodgkin lymphoma autologous EBV CTLs NCT01192464 
   first generation  
   autologous T cells NCT01316146 
   second generation (CD28)  
Baylor/Texas Children's Hospital GD2 neuroblastoma autologous EBV CTLs NCT00085930 
   first generation  
   autologous polyclonal CTLs  
   first generation  

Abbreviations: BMT, bone marrow transplant; CMV, cytomegalovirus; CTL, cytotoxic T lymphocyte; LCL, lymphoblastic cell line; SCT, stem cell transplantation.

Choosing CAR targets for solid tumors is potentially more challenging because solid-tumor–associated antigens often coexist on nonexpendable tissues. GD2 is a validated tumor antigen for which mAb-based targeting has proved to be safe (38). Efforts to target GD2 with mAbs are reviewed by Matthay and colleagues in this CCR Focus section (39). Not surprisingly, therefore, one of the first trials of CAR therapy used a GD2-CAR administered to children with advanced neuroblastoma. In that study, 3 of 11 patients with active disease experienced complete responses, no substantial toxicity was observed, and sustained clinical benefit was reported for several patients with long-term follow-up (1, 2). Of note, the CARs used in this trial were of the first-generation variety and incorporated only CD3 ζ chain signaling motifs. Current approaches that incorporate costimulatory signaling motifs may be even more active. In contrast to the favorable safety profile seen when targeting GD2, CAR therapy used to target Her2/Neu resulted in a patient death that was attributed to Her2/Neu expression on normal lung and/or cardiac tissue (40). It is important to note, however, that substantially higher numbers of CAR-transduced cells were administered in this case than were administered in many other trials, raising the prospect that lower doses of CARs targeting this antigen might also be safe. Indeed, a cautious dose-escalation study is under way in pediatric patients with osteosarcoma to determine whether Her2/Neu-CAR T cells have acceptable risk–benefit ratios (http://clinicaltrials.gov/ct2/show/NCT00902044). Nonetheless, this clinical experience illustrates that antigens that are safely targeted by antibody therapy cannot necessarily be assumed to be safe when targeted with CARs.

A full list of potential targets for CAR-based therapy of pediatric solid tumors is beyond the scope of this report, but this is an area of very active investigation (for review, see ref. 41). Targets that are currently under study include epidermal growth factor receptor (EGFR) vIII (42) and interleukin (IL)-13 receptor α2 (32, 43), both of which are expressed on a substantial number of pediatric gliomas. B7H3 is expressed by many sarcomas and pediatric brain tumors (44), and fibroblast growth receptor 2 (FGFR2) is highly expressed by most rhabdomyosarcomas (45). Substantially more work is needed to prioritize targets for testing in early clinical trials of CAR therapy in pediatric oncology, and this will be based on preclinical studies of killing activity and the relative risk of off-target effects.

Several groups have developed clinical-grade cell-manufacturing systems that are capable of producing large numbers of CAR-modified T cells. There is wide variation in the specific processes used, and to date there is no clear evidence that one is superior to another, although this remains an area of active investigation. One of the most commonly used methods employs anti-CD3 plus autologous or allogeneic feeder cells and high-dose IL-2 (Fig. 2A, I; refs. 46–49). Alternatively, artificial antigen-presenting cells (aAPC) that provide anti-CD3 plus costimulatory signals have been developed in an effort to replicate the physiologic process of T-cell activation by dendritic cells. Cell-based aAPCs, most often K562 cells modified to express costimulatory ligands (4-1BBL, CD80) and/or cytokines (IL-15 and IL-21), induce potent expansion of both natural killer cells and/or T cells (Fig. 2A, II; refs. 50–53). Bead-based aAPCs (Fig. 2A, III) employing anti-CD3 and anti-CD28 antibodies coupled to paramagnetic beads induce robust T-cell expansion without the need for exogenous cytokines (54, 55). All of these methods are sufficient to generate a several-hundred-fold expansion of cells over a 10- to 14-day period (Fig. 2B). In addition, investigators have developed approaches to expand donor or patient Epstein–Barr virus (EBV)- and cytomegalovirus (CMV)-specific T cells using viral antigens that engage endogenous TCRs and costimulatory pathways before and after CAR transduction (1, 18, 56). Such virus-specific T cells could prove useful for administering CAR T cells following allogeneic hematopoietic stem cell transplant because they are not predicted to induce graft-versus-host disease. In addition, the investigators hypothesize that exposure to intermittent viral reactivation in vivo will contribute to persistence following transfer. However, the production of CAR-modified, virus-specific cells generally requires a longer culture period compared with the polyclonal techniques described above (18).

Figure 2.

General schema for the preparation, transduction, and infusion of CAR-modified T cells. A, apheresed T cells from a patient or an allogeneic donor are activated. Three accepted methods are illustrated: (i) stimulation with the activating CD3 antibody, OKT3, in the presence of IL-2; (ii) stimulation with anti-CD3– and anti-CD28–coated paramagnetic beads in the presence of IL-2; and (iii) stimulation with aAPC (expressing 4-1BBL and an Fc receptor) with OKT3 and IL-2. Activated cells are then transduced with the CAR using a retro- or lentiviral platform. Because the CAR is integrated into the T-cell genome, all daughter cells that are generated (a mix of CD4+ [Th1/Th2/TH17/Treg] and CD8+ T cells) during this expansion also express the CAR. CAR T cells are then infused into the patient after preparative chemotherapy. B, generation of CAR-expressing T cells generally results in a several-hundred-fold expansion over 14 days. Such extensive proliferation may generate predominantly TEFF cells, which have cytotoxic capabilities but limited proliferative potential compared with T-effector and TCM cells. C, less intense stimulation and/or modulation of stimulation methods may produce more naïve T cells or T-central memory cells, which have an increased likelihood of persistence.

Figure 2.

General schema for the preparation, transduction, and infusion of CAR-modified T cells. A, apheresed T cells from a patient or an allogeneic donor are activated. Three accepted methods are illustrated: (i) stimulation with the activating CD3 antibody, OKT3, in the presence of IL-2; (ii) stimulation with anti-CD3– and anti-CD28–coated paramagnetic beads in the presence of IL-2; and (iii) stimulation with aAPC (expressing 4-1BBL and an Fc receptor) with OKT3 and IL-2. Activated cells are then transduced with the CAR using a retro- or lentiviral platform. Because the CAR is integrated into the T-cell genome, all daughter cells that are generated (a mix of CD4+ [Th1/Th2/TH17/Treg] and CD8+ T cells) during this expansion also express the CAR. CAR T cells are then infused into the patient after preparative chemotherapy. B, generation of CAR-expressing T cells generally results in a several-hundred-fold expansion over 14 days. Such extensive proliferation may generate predominantly TEFF cells, which have cytotoxic capabilities but limited proliferative potential compared with T-effector and TCM cells. C, less intense stimulation and/or modulation of stimulation methods may produce more naïve T cells or T-central memory cells, which have an increased likelihood of persistence.

Close modal

Cells that have been expanded in each of the above systems are amenable to transduction, secrete cytokines, and lyse antigen-expressing cells (57, 58); however, emerging studies suggest that the nature of the starting cell population that is genetically modified and/or the method of expansion may affect the likelihood that CAR T cells will persist in vivo and effectively mediate antitumor effects. In models that emphasized generation of larger doses of CAR T cells at the expense of driving them toward short-lived T-effector cells (Fig. 2C), recent studies of adoptive immunotherapy correlated clinical benefit with in vivo cell expansion and persistence (2, 59–61). In a recent clinical study, administration of a very low number of CAR-specific T cells, calculated to yield an effector:target ratio of 1 CAR-transduced T cell to 93,000 CLL cells, yielded a dramatic clinical benefit (1, 3). This finding and the observation that administration of small numbers of T cells can mediate dramatic effects against large tumor burdens (62) emphasize the notion that cells that are capable of robust proliferation can overcome daunting tumor burdens.

Data gleaned from a variety of murine and human studies of adoptive T-cell immunotherapy show that cells bearing a terminally differentiated T-effector memory (TEM) phenotype, which tend to dominate prolonged ex vivo cultures and systems using anti-CD3 plus IL-2, have a limited capacity to expand and persist in vivo following an encounter with the tumor (63). In contrast, T-central memory (TCM) cells are more potent in several models (64), and it is predicted that this subset may be more effective in the setting of CAR-transduced T cells as well. Some studies showed enhanced efficacy when TCM cells were used as a starting population for transduction (65), whereas in other studies investigators focused on expanding TCM cells using APC-based systems (66). Surprisingly, in some cases, TCM cells emerged in vivo following administration of a mixed population of predominantly TEM cells (64). Virus-specific T cells showed enhanced persistence compared with nonviral CAR T cells, perhaps due to an increased frequency of TCM in virus-specific populations (1). Recently, a new subset termed T stem cell memory (TSCM) performed better than TCM and TEM in a preclinical model of CARs directed against the tumor antigen mesothelin (67). Studies are under way to determine optimal approaches for generating or maintaining TSCM cells during expansion, and several agents, including rapamycin, IL-21 (26, 68), and Wnt signaling modulators (69), appear to be capable of limiting terminal differentiation and/or enhancing TSCM cells. Finally, recent data suggest that the efficacy of CAR T-cell products correlates with the number of CD4+ T cells infused (2), and historical data provide evidence that CD4+ T cells themselves support the persistence of CD8+ T cells (70). Of interest, bead-based aAPCs preferentially expand CD4+ T cells compared with most other approaches (26, 66). Although CD4+ regulatory T cells (Treg) theoretically could be transduced with a CAR or develop from a non-Treg that was CAR transduced (Fig. 2A), culture conditions do not seem to select for this subset, and there is no evidence thus far that CAR-transduced Tregs mediate clinically significant immunosuppression.

Given the multitude of cell subsets that can be targeted with CAR therapy, and the vast array of approaches that can be used to transduce and expand CAR T cells, it would be highly desirable to obtain accurate preclinical models to predict clinical efficacy. Unfortunately, for most CARs, such studies are limited to xenograft models that incorporate adoptive transfer of human tumors and human T cells into immunodeficient mice. Although such models provide some insights into clinical activity, they may not provide an accurate assessment of persistence in humans, and provide little insight into toxicity, including CAR T-cell–induced autoimmunity. Fully murine models may be preferable but are not available for most CARs currently under study in humans. Thus, optimizing preclinical models to prioritize targets and cell-manufacturing methods represents an important area for future efforts.

Early studies of adoptive immunotherapy focused on generating large quantities of antigen-specific effectors to overcome the perceived limitations posed by overwhelming tumor cell numbers compared with available effectors. In contrast, current efforts are more focused on administering cells with robust proliferative capacity, and modulating the host immune milieu to support in vivo expansion and persistence. Lymphopenia induces profound changes in T-cell physiology, due primarily to accumulation of IL-7 and IL-15, homeostatic cytokines that support T-cell expansion and survival (71–73). As a result, most adoptive cell therapy protocols incorporate lymphotoxic therapies prior to cell transfer to increase the availability of such homeostatic cytokines. The results of nonrandomized trials support this approach (7, 74), but no definitive data are available to confirm that it is necessary.

In pediatric oncology, most candidates for adoptive immunotherapy are already lymphopenic due to previous exposure to cytotoxic regimens. GD2-CAR therapy administered without a lymphodepleting regimen showed antitumor activity in patients with neuroblastoma (1, 2), although it remains unclear to what extent these patients were lymphopenic at the time cell therapy was initiated. Lymphodepleting regimens may also enhance the efficacy of adoptive cell therapies by transiently reducing Treg numbers (75), and by inducing mucosal damage that results in systemic exposure to lipopolysaccharide and other bacterial byproducts, which activate the innate immune system (Fig. 3; refs. 76, 77). Preclinical models show that administration of homeostatic cytokines combined with targeted therapies to induce Treg depletion is more effective than nonspecific cytotoxic regimens in supporting adoptive immunotherapy (78). Therefore, efforts are under way to induce or administer the essential host factors that will support adoptively transferred cells while limiting the toxicity of the regimen. This is particularly relevant for the field of pediatric oncology, where the desire to limit late effects is a major factor driving the development of targeted therapies such as CAR-based regimens.

Figure 3.

Lymphodepleting preparatory regimens can enhance the efficacy of adoptive cell therapy. Proposed mechanisms include (i) a reduction in endogenous lymphocytes, leading to accumulation of IL-7 and IL-15 (homeostatic cytokines that support cell expansion and persistence); (ii) a transient reduction in the number and frequency of Tregs, thereby diminishing suppression; and (iii) induction of gut damage, which can lead to the systemic release of bacterial byproducts [e.g., lipopolysaccharide (LPS)] that activate the innate immune system.

Figure 3.

Lymphodepleting preparatory regimens can enhance the efficacy of adoptive cell therapy. Proposed mechanisms include (i) a reduction in endogenous lymphocytes, leading to accumulation of IL-7 and IL-15 (homeostatic cytokines that support cell expansion and persistence); (ii) a transient reduction in the number and frequency of Tregs, thereby diminishing suppression; and (iii) induction of gut damage, which can lead to the systemic release of bacterial byproducts [e.g., lipopolysaccharide (LPS)] that activate the innate immune system.

Close modal

At the present time, because of the complexity and cost of generating CAR-based therapies, only a few specialized centers are capable of delivering such products. Further, the approach is currently supported entirely by academia, government, and private sources; to date, no biotechnology or pharmaceutical company has sponsored a CAR trial. Despite these limitations, however, several clinical trials have already been completed and many others are currently under way or planned, including some in pediatrics. Several key elements of successful CAR therapy have been elucidated in these trials. First, a proof-of-principle that CAR therapy can mediate a clinical benefit against childhood cancers was provided in the first trial undertaken in pediatrics. Most trials that used CARs lacking costimulatory motifs were unsuccessful due to poor persistence and/or expansion of the transduced T cells; however, a clinical trial of anti-GD2 CAR T cells in 19 patients with neuroblastoma who received a mixture of autologous, CAR-modified EBV-cytotoxic T lymphocytes (CTL) and anti-CD3–activated polyclonal CAR-modified T cells proved to be an exception (1, 2). These patients did not receive a preparative regimen, although they may have already been lymphopenic due to extensive prior therapy. Three of 11 evaluable patients had a complete response, and improved clinical outcomes were observed in patients in whom CAR T cells could be detected beyond 6 weeks. In this trial, improved clinical outcomes also correlated with higher levels of CD4+ cells and higher levels of central memory cells in the infused adoptive cell product (2). Of interest, although pain associated with anti-GD2 mAb therapy is commonly seen, no significant GD2-CAR–associated pain was observed in this trial, raising the prospect that in some cases, CAR-based therapy could be less toxic than mAb therapy.

Clinical trials in adults have provided evidence that CD19 is a safe and effective target for CAR therapy of B-cell malignancies (3, 4, 19). In these studies, patients who experienced clinically meaningful responses with lysis of large tumor burdens and maintenance of complete responses showed massive expansion of the infused cells, and persistence of cells for at least 6 to 12 months. Thus, clinical activity has been observed in several CAR clinical trials, including those targeting CD19 and GD2, both of which are antigens expressed on pediatric tumors. Several groups have shown that incorporation of a costimulatory domain(s) into a CAR leads to increased persistence (17, 79, 80), and results from nonrandomized studies suggest that a lymphodepleting regimen improves outcomes (60, 77, 80). Therefore, most studies that are currently planned or under way in pediatrics will incorporate costimulatory elements in the CAR design and use a lymphodepleting regimen prior to adoptive transfer.

These early successes with CAR therapy, however, were not achieved without substantial toxicities. Flu-like symptoms such as fever, malaise, and myalgias are common after CAR T-cell infusion and likely relate to cytokine release by the infused cells, because they coincide with increases in IFN-γ (19). As discussed earlier, one adult patient treated with 1010 highly activated Her2/Neu-CAR T cells developed fatal immune activation syndrome resulting from low-level target expression in the lungs shortly after CAR T-cell infusion (40, 81). A second patient who received cyclophosphamide conditioning followed by 3 × 107/kg anti-CD19 CAR T cells developed exacerbation of preexisting immune activation, presumably from an underlying infection, 6 hours after cell infusion and ultimately died (81, 82). As a result of these toxicities, recent trials have decreased the number of infused CAR cells in the initial cohorts (generally starting at 106/kg), and incorporated close monitoring of clinical symptoms and serum cytokine levels. Other observed toxicities include autoimmunity mediated by on-target, off-tissue effects (e.g., hepatic toxicity) resulting from therapy with carbonic anhydrase IX-CAR, which has since been shown to be expressed on cells in the biliary tract (23). Furthermore, anti-CAR immune responses (23) may adversely affect the efficacy of the therapy itself.

Dramatic progress in our understanding of genomics (83, 84), cancer biology (85), and immunology (39) is fueling exciting new progress in the search for more effective and less toxic targeted therapies for childhood cancer (86). Among the most novel and promising of these approaches are CAR-based cell therapies that combine advances in genetic engineering and adoptive immunotherapy. Current research focused on optimizing this approach emphasizes (i) effective tumor targeting with limited off-tumor toxicity, (ii) optimized cell manufacturing to improve efficacy and render the therapies more exportable, and (iii) modulation of the host and/or cell product to increase in vivo expansion and/or persistence. In pediatric cancers, several candidate antigens have already been identified that provide acceptable tumor targeting, but much more work is needed in this arena, especially for pediatric solid tumors. Cell-surface antigens with robust tumor expression and limited normal tissue expression that could be effectively and safely targeted with this therapy must be systematically identified and prioritized. With regard to optimizing cell manufacturing, it is clear that many different approaches can reliably generate large numbers of CAR-expressing T cells. However, better preclinical models and surrogates for bioactivity are needed to compare manufacturing approaches, and carefully controlled clinical trials are needed to directly test the various CAR constructs and expansion techniques that are currently available. Finally, optimal modulation of host factors is also likely a key determinant of in vivo expansion and persistence, and recent insights suggest that lymphopenic hosts that receive cells bearing TCM or TSCM phenotypes experience optimal antitumor effects. Given the limitation in patient numbers that challenges early-phase pediatric trials, we anticipate that seminal insights in each of these arenas will be gleaned from clinical trials that are under way in adult oncology, or in trials that enroll both adult and pediatric patients. Ultimately, however, careful clinical trials in children will be needed to assess efficacy and oxicity. If favorable antitumor effects are observed, we anticipate that progress in manufacturing techniques will lead to reductions in the cost and complexity of generating these therapies, allowing them to be exported and/or made available to institutions where such approaches are currently not available.

We envision that CAR-based therapies will ultimately comprise multimodal regimens, likely incorporating host preparative regimens, novel elements in the cell expansion cocktail, and potentially cytokines to maximize in vivo expansion. Although most immunotherapies seem to be most active in the setting of minimal residual disease, impressive antitumor effects observed thus far in a small number of patients with bulky disease raise the prospect that CAR-based therapies may have activity in the setting of large tumor burdens. For studies undertaken in the setting of minimal residual disease, novel clinical trial endpoints are needed to determine whether results from early-phase trials warrant larger randomized trials with survival endpoints. Careful clinical trials will be needed to assess the optimal timing for incorporating CAR-based adoptive immunotherapies, and to compare CAR-based targeting of cell-surface antigens with mAb-based immunotherapies. In summary, CARs represent a novel and promising approach for targeted therapy of childhood cancer. Progress in this arena will be largely driven by academia and will require support for expensive early-phase clinical trials that promise to pave the way for a new form of targeted, exportable immunotherapy for children with cancer.

No potential conflicts of interest were disclosed.

Conception and design: D.W. Lee, D.M. Barrett, C.L. Mackall, R.J. Orentas, S.A. Grupp

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.W. Lee, R.J. Orentas, S.A. Grupp

Writing, review, and/or revision of the manuscript: D.W. Lee, D.M. Barrett, C.L. Mackall, R.J. Orentas, S.A. Grupp,

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D.W. Lee, R.J. Orentas

1.
Pule
MA
,
Savoldo
B
,
Myers
GD
,
Rossig
C
,
Russell
HV
,
Dotti
G
, et al
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
.
Nat Med
2008
;
14
:
1264
70
.
2.
Louis
CU
,
Savoldo
B
,
Dotti
G
,
Pule
M
,
Yvon
E
,
Myers
GD
, et al
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
.
Blood
2011
;
118
:
6050
6
.
3.
Porter
DL
,
Levine
BL
,
Kalos
M
,
Bagg
A
,
June
CH
. 
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
.
N Engl J Med
2011
;
365
:
725
33
.
4.
Kochenderfer
JN
,
Wilson
WH
,
Janik
JE
,
Dudley
ME
,
Stetler-Stevenson
M
,
Feldman
SA
, et al
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
.
Blood
2010
;
116
:
4099
102
.
5.
Robbins
PF
,
Morgan
RA
,
Feldman
SA
,
Yang
JC
,
Sherry
RM
,
Dudley
ME
, et al
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
.
J Clin Oncol
2011
;
29
:
917
24
.
6.
Morgan
RA
,
Dudley
ME
,
Wunderlich
JR
,
Hughes
MS
,
Yang
JC
,
Sherry
RM
, et al
Cancer regression in patients after transfer of genetically engineered lymphocytes
.
Science
2006
;
314
:
126
9
.
7.
Dudley
ME
,
Yang
JC
,
Sherry
R
,
Hughes
MS
,
Royal
R
,
Kammula
U
, et al
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
.
J Clin Oncol
2008
;
26
:
5233
9
.
8.
Eshhar
Z
,
Waks
T
,
Gross
G
,
Schindler
DG
. 
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
.
Proc Natl Acad Sci U S A
1993
;
90
:
720
4
.
9.
Friedmann-Morvinski
D
,
Bendavid
A
,
Waks
T
,
Schindler
D
,
Eshhar
Z
. 
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation
.
Blood
2005
;
105
:
3087
93
.
10.
Gross
G
,
Waks
T
,
Eshhar
Z
. 
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
.
Proc Natl Acad Sci U S A
1989
;
86
:
10024
8
.
11.
Okur
FV
,
Brenner
MK
. 
Cellular immunotherapy of cancer
.
Methods Mol Biol
2010
;
651
:
319
45
.
12.
Finney
HM
,
Akbar
AN
,
Lawson
AD
. 
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
.
J Immunol
2004
;
172
:
104
13
.
13.
Imai
C
,
Mihara
K
,
Andreansky
M
,
Nicholson
IC
,
Pui
CH
,
Geiger
TL
, et al
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
.
Leukemia
2004
;
18
:
676
84
.
14.
Maher
J
,
Brentjens
RJ
,
Gunset
G
,
Rivière
I
,
Sadelain
M
. 
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor
.
Nat Biotechnol
2002
;
20
:
70
5
.
15.
Milone
MC
,
Fish
JD
,
Carpenito
C
,
Carroll
RG
,
Binder
GK
,
Teachey
D
, et al
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
.
Mol Ther
2009
;
17
:
1453
64
.
16.
Gong
MC
,
Latouche
JB
,
Krause
A
,
Heston
WD
,
Bander
NH
,
Sadelain
M
. 
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen
.
Neoplasia
1999
;
1
:
123
7
.
17.
Kowolik
CM
,
Topp
MS
,
Gonzalez
S
,
Pfeiffer
T
,
Olivares
S
,
Gonzalez
N
, et al
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
.
Cancer Res
2006
;
66
:
10995
1004
.
18.
Savoldo
B
,
Rooney
CM
,
Di Stasi
A
,
Abken
H
,
Hombach
A
,
Foster
AE
, et al
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
.
Blood
2007
;
110
:
2620
30
.
19.
Kalos
M
,
Levine
BL
,
Porter
DL
,
Katz
S
,
Grupp
SA
,
Bagg
A
, et al
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
.
Sci Transl Med
2011
;
3
:
95ra73
.
20.
Kochenderfer
JN
,
Feldman
SA
,
Zhao
YB
,
Xu
H
,
Black
MA
,
Morgan
RA
, et al
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
.
J Immunother
2009
;
32
:
689
702
.
21.
Lam
JS
,
Reeves
ME
,
Cowherd
R
,
Rosenberg
SA
,
Hwu
P
. 
Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope
.
Hum Gene Ther
1996
;
7
:
1415
22
.
22.
Burns
WR
,
Zheng
Z
,
Rosenberg
SA
,
Morgan
RA
. 
Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
.
Blood
2009
;
114
:
2888
99
.
23.
Lamers
CH
,
Willemsen
R
,
van Elzakker
P
,
van Steenbergen-Langeveld
S
,
Broertjes
M
,
Oosterwijk-Wakka
J
, et al
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
.
Blood
2011
;
117
:
72
82
.
24.
Zhao
Y
,
Zheng
Z
,
Cohen
CJ
,
Gattinoni
L
,
Palmer
DC
,
Restifo
NP
, et al
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation
.
Mol Ther
2006
;
13
:
151
9
.
25.
Singh
H
,
Manuri
PR
,
Olivares
S
,
Dara
N
,
Dawson
MJ
,
Huls
H
, et al
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system
.
Cancer Res
2008
;
68
:
2961
71
.
26.
Singh
H
,
Figliola
MJ
,
Dawson
MJ
,
Huls
H
,
Olivares
S
,
Switzer
K
, et al
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies
.
Cancer Res
2011
;
71
:
3516
27
.
27.
Barrett
DM
,
Zhao
Y
,
Liu
X
,
Jiang
S
,
Carpenito
C
,
Kalos
M
, et al
Treatment of advanced leukemia in mice with mRNA engineered T cells
.
Hum Gene Ther
2011
;
22
:
1575
86
.
28.
Hoyos
V
,
Savoldo
B
,
Quintarelli
C
,
Mahendravada
A
,
Zhang
M
,
Vera
J
, et al
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
.
Leukemia
2010
;
24
:
1160
70
.
29.
Cooper
LJ
,
Ausubel
L
,
Gutierrez
M
,
Stephan
S
,
Shakeley
R
,
Olivares
S
, et al
Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma
.
Cytotherapy
2006
;
8
:
105
17
.
30.
Di Stasi
A
,
Tey
SK
,
Dotti
G
,
Fujita
Y
,
Kennedy-Nasser
A
,
Martinez
C
, et al
Inducible apoptosis as a safety switch for adoptive cell therapy
.
N Engl J Med
2011
;
365
:
1673
83
.
31.
Stastny
MJ
,
Brown
CE
,
Ruel
C
,
Jensen
MC
. 
Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells
.
J Pediatr Hematol Oncol
2007
;
29
:
669
77
.
32.
Kahlon
KS
,
Brown
C
,
Cooper
LJ
,
Raubitschek
A
,
Forman
SJ
,
Jensen
MC
. 
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells
.
Cancer Res
2004
;
64
:
9160
6
.
33.
Wang
J
,
Jensen
M
,
Lin
Y
,
Sui
X
,
Chen
E
,
Lindgren
CG
, et al
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
.
Hum Gene Ther
2007
;
18
:
712
25
.
34.
Wang
J
,
Press
OW
,
Lindgren
CG
,
Greenberg
P
,
Riddell
S
,
Qian
X
, et al
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes
.
Mol Ther
2004
;
9
:
577
86
.
35.
James
SE
,
Greenberg
PD
,
Jensen
MC
,
Lin
Y
,
Wang
J
,
Till
BG
, et al
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane
.
J Immunol
2008
;
180
:
7028
38
.
36.
Di Stasi
A
,
De Angelis
B
,
Rooney
CM
,
Zhang
L
,
Mahendravada
A
,
Foster
AE
, et al
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
.
Blood
2009
;
113
:
6392
402
.
37.
Hudecek
M
,
Schmitt
TM
,
Baskar
S
,
Lupo-Stanghellini
MT
,
Nishida
T
,
Yamamoto
TN
, et al
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
.
Blood
2010
;
116
:
4532
41
.
38.
Yu
AL
,
Gilman
AL
,
Ozkaynak
MF
,
London
WB
,
Kreissman
SG
,
Chen
HX
, et al
Children's Oncology Group
. 
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
.
N Engl J Med
2010
;
363
:
1324
34
.
39.
Matthay
KK
,
George
RE
,
Yu
AL
. 
Promising therapeutic targets in neuroblastoma
.
Clin Cancer Res
2012
;
18
:
2740
53
.
40.
Morgan
RA
,
Yang
JC
,
Kitano
M
,
Dudley
ME
,
Laurencot
CM
,
Rosenberg
SA
. 
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
.
Mol Ther
2010
;
18
:
843
51
.
41.
Orentas
RJLD
,
Mackall
C
. 
Immunotherapy targets in pediatric cancer
.
Front Pediatr Oncol
2012
;
2
:
1
16
.
42.
Bax
DA
,
Gaspar
N
,
Little
SE
,
Marshall
L
,
Perryman
L
,
Regairaz
M
, et al
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines
.
Clin Cancer Res
2009
;
15
:
5753
61
.
43.
Kioi
M
,
Seetharam
S
,
Puri
RK
. 
Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin
.
Mol Cancer Ther
2008
;
7
:
1579
87
.
44.
Luther
N
,
Cheung
NK
,
Souliopoulos
EP
,
Karampelas
I
,
Bassiri
D
,
Edgar
MA
, et al
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38
.
Mol Cancer Ther
2010
;
9
:
1039
46
.
45.
Taylor
JG
 6th
,
Cheuk
AT
,
Tsang
PS
,
Chung
JY
,
Song
YK
,
Desai
K
, et al
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models
.
J Clin Invest
2009
;
119
:
3395
407
.
46.
Padula
SJ
,
Pollard
MK
,
Lingenheld
EG
,
Clark
RB
. 
Maintenance of antigen specificity by human interleukin-2-dependent T cell lines. Use of antigen-presenting cells and OKT3 antibody in the absence of antigen
.
J Clin Invest
1985
;
75
:
788
97
.
47.
Ochoa
AC
,
Hasz
DE
,
Rezonzew
R
,
Anderson
PM
,
Bach
FH
. 
Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets
.
Cancer Res
1989
;
49
:
963
8
.
48.
Hoyle
C
,
Bangs
CD
,
Chang
P
,
Kamel
O
,
Mehta
B
,
Negrin
RS
. 
Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice
.
Blood
1998
;
92
:
3318
27
.
49.
Goedegebuure
PS
,
Douville
LM
,
Li
H
,
Richmond
GC
,
Schoof
DD
,
Scavone
M
, et al
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study
.
J Clin Oncol
1995
;
13
:
1939
49
.
50.
Imai
C
,
Iwamoto
S
,
Campana
D
. 
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
.
Blood
2005
;
106
:
376
83
.
51.
Lee
DA
,
Verneris
MR
,
Campana
D
. 
Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy
.
Methods Mol Biol
2010
;
651
:
61
77
.
52.
Li
L
,
Liu
LN
,
Feller
S
,
Allen
C
,
Shivakumar
R
,
Fratantoni
J
, et al
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
.
Cancer Gene Ther
2010
;
17
:
147
54
.
53.
Suhoski
MM
,
Golovina
TN
,
Aqui
NA
,
Tai
VC
,
Varela-Rohena
A
,
Milone
MC
, et al
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules
.
Mol Ther
2007
;
15
:
981
8
.
54.
Levine
BL
,
Bernstein
WB
,
Connors
M
,
Craighead
N
,
Lindsten
T
,
Thompson
CB
, et al
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells
.
J Immunol
1997
;
159
:
5921
30
.
55.
Garlie
NK
,
LeFever
AV
,
Siebenlist
RE
,
Levine
BL
,
June
CH
,
Lum
LG
. 
T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer
.
J Immunother
1999
;
22
:
336
45
.
56.
Biagi
E
,
Marin
V
,
Attianese
GM
,
Pizzitola
I
,
Tettamanti
S
,
Cribioli
E
, et al
New advances in leukaemia immunotherapy by the use of chimeric artificial antigen receptors (CARs): state of the art and perspectives for the near future
.
Ital J Pediatr
2011
;
37
:
46
.
57.
Carlens
S
,
Gilljam
M
,
Remberger
M
,
Aschan
J
,
Christensson
B
,
Dilber
MS
. 
Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution
.
Exp Hematol
2000
;
28
:
1137
46
.
58.
Stockschläder
M
,
Haiss
M
,
Exner
S
,
Schmah
O
,
Veelken
H
,
Follo
M
, et al
Expansion and fibronectin-enhanced retroviral transduction of primary human T lymphocytes for adoptive immunotherapy
.
J Hematother Stem Cell Res
1999
;
8
:
401
10
.
59.
Robbins
PF
,
Dudley
ME
,
Wunderlich
J
,
El-Gamil
M
,
Li
YF
,
Zhou
J
, et al
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
.
J Immunol
2004
;
173
:
7125
30
.
60.
Brentjens
RJ
,
Rivière
I
,
Park
JH
,
Davila
ML
,
Wang
X
,
Stefanski
J
, et al
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
.
Blood
2011
;
118
:
4817
28
.
61.
Yee
C
,
Thompson
JA
,
Byrd
D
,
Riddell
SR
,
Roche
P
,
Celis
E
, et al
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells
.
Proc Natl Acad Sci U S A
2002
;
99
:
16168
73
.
62.
Hunder
NN
,
Wallen
H
,
Cao
J
,
Hendricks
DW
,
Reilly
JZ
,
Rodmyre
R
, et al
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
.
N Engl J Med
2008
;
358
:
2698
703
.
63.
Gattinoni
L
,
Klebanoff
CA
,
Palmer
DC
,
Wrzesinski
C
,
Kerstann
K
,
Yu
Z
, et al
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
.
J Clin Invest
2005
;
115
:
1616
26
.
64.
Powell
DJ
 Jr
,
Dudley
ME
,
Robbins
PF
,
Rosenberg
SA
. 
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy
.
Blood
2005
;
105
:
241
50
.
65.
Berger
C
,
Jensen
MC
,
Lansdorp
PM
,
Gough
M
,
Elliott
C
,
Riddell
SR
. 
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
.
J Clin Invest
2008
;
118
:
294
305
.
66.
Paulos
CM
,
Suhoski
MM
,
Plesa
G
,
Jiang
T
,
Basu
S
,
Golovina
TN
, et al
Adoptive immunotherapy: good habits instilled at youth have long-term benefits
.
Immunol Res
2008
;
42
:
182
96
.
67.
Gattinoni
L
,
Lugli
E
,
Ji
Y
,
Pos
Z
,
Paulos
CM
,
Quigley
MF
, et al
A human memory T cell subset with stem cell-like properties
.
Nat Med
2011
;
17
:
1290
7
.
68.
Hinrichs
CS
,
Spolski
R
,
Paulos
CM
,
Gattinoni
L
,
Kerstann
KW
,
Palmer
DC
, et al
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
.
Blood
2008
;
111
:
5326
33
.
69.
Gattinoni
L
,
Zhong
XS
,
Palmer
DC
,
Ji
Y
,
Hinrichs
CS
,
Yu
Z
, et al
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
.
Nat Med
2009
;
15
:
808
13
.
70.
Walter
EA
,
Greenberg
PD
,
Gilbert
MJ
,
Finch
RJ
,
Watanabe
KS
,
Thomas
ED
, et al
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
.
N Engl J Med
1995
;
333
:
1038
44
.
71.
Fry
TJ
,
Connick
E
,
Falloon
J
,
Lederman
MM
,
Liewehr
DJ
,
Spritzler
J
, et al
A potential role for interleukin-7 in T-cell homeostasis
.
Blood
2001
;
97
:
2983
90
.
72.
Thiant
S
,
Yakoub-Agha
I
,
Magro
L
,
Trauet
J
,
Coiteux
V
,
Jouet
JP
, et al
Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse
.
Bone Marrow Transplant
2010
;
45
:
1546
52
.
73.
Klebanoff
CA
,
Khong
HT
,
Antony
PA
,
Palmer
DC
,
Restifo
NP
. 
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
.
Trends Immunol
2005
;
26
:
111
7
.
74.
Rosenberg
SA
,
Yang
JC
,
Sherry
RM
,
Kammula
US
,
Hughes
MS
,
Phan
GQ
, et al
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
.
Clin Cancer Res
2011
;
17
:
4550
7
.
75.
Zhang
H
,
Chua
KS
,
Guimond
M
,
Kapoor
V
,
Brown
MV
,
Fleisher
TA
, et al
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells
.
Nat Med
2005
;
11
:
1238
43
.
76.
Paulos
CM
,
Wrzesinski
C
,
Kaiser
A
,
Hinrichs
CS
,
Chieppa
M
,
Cassard
L
, et al
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
.
J Clin Invest
2007
;
117
:
2197
204
.
77.
Wrzesinski
C
,
Paulos
CM
,
Kaiser
A
,
Muranski
P
,
Palmer
DC
,
Gattinoni
L
, et al
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells
.
J Immunother
2010
;
33
:
1
7
.
78.
Cui
Y
,
Zhang
H
,
Meadors
J
,
Poon
R
,
Guimond
M
,
Mackall
CL
. 
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts
.
Blood
2009
;
114
:
3831
40
.
79.
Zhao
Y
,
Wang
QJ
,
Yang
S
,
Kochenderfer
JN
,
Zheng
Z
,
Zhong
X
, et al
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
.
J Immunol
2009
;
183
:
5563
74
.
80.
Brentjens
RJ
,
Santos
E
,
Nikhamin
Y
,
Yeh
R
,
Matsushita
M
,
La Perle
K
, et al
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts
.
Clin Cancer Res
2007
;
13
:
5426
35
.
81.
Ertl
HC
,
Zaia
J
,
Rosenberg
SA
,
June
CH
,
Dotti
G
,
Kahn
J
, et al
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010
.
Cancer Res
2011
;
71
:
3175
81
.
82.
Brentjens
R
,
Yeh
R
,
Bernal
Y
,
Riviere
I
,
Sadelain
M
. 
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial
.
Mol Ther
2010
;
18
:
666
8
.
83.
Loh
ML
,
Mullighan
CG
. 
Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy
.
Clin Cancer Res
2012
;
18
:
2754
67
.
84.
Pinto
N
,
Cohn
SL
,
Dolan
ME
. 
Using germline genomics to individualize pediatric cancer treatments
.
Clin Cancer Res
2012
;
18
:
2791
800
.
85.
Lawlor
ER
,
Thiele
CJ
. 
Epigenetic changes in pediatric solid tumors: promising new targets
.
Clin Cancer Res
2012
;
18
:
2768
79
.
86.
Thiele
CJ
,
Cohn
SL
. 
Genetically InFormed Therapies—a “GIFT” for children with cancer
.
Clin Cancer Res
2012
;
18
:
2735
9
.